0800 Immune

0800 466 863

Pertussis Immunisation in Pregnancy Safety (PIPS) Study: A retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine

Background: New Zealand has funded the administration of tetanus, diphtheria and acellular pertussis
(Tdap) vaccine during pregnancy to prevent infant pertussis since 2013. The aim of this study was to
assess the safety of Tdap vaccine administered to pregnant women as part of a national maternal immunisation
programme.
Methods: We conducted a national retrospective observational study using linked administrative New
Zealand datasets. The study population consisted of pregnant women eligible to receive funded Tdap vaccination
from 28 to 38 weeks gestation in 2013. Primary study outcomes were based on prioritised adverse
events for the assessment of vaccine safety in pregnant women, as defined by WHO and Brighton
Collaboration taskforces. We examined the effect of Tdap vaccination on prioritised maternal outcomes
using Cox proportional hazard models. Adjusted hazard ratios controlled for key confounding variables.
Results: In the cohort of 68,550 women eligible to receive funded antenatal Tdap vaccination during 2013,
8178 (11.9%) were vaccinated and 60,372 (88.1%) were unvaccinated. The use of Tdap in pregnancy was not
associated with an increase in the rate of primary outcomes, including preterm labour; pre-eclampsia;
pre-eclampsia with severe features; eclampsia; gestational hypertension; fetal growth restriction; or
post-partum haemorrhage. Tdap also did not increase secondary outcomes, including gestational diabetes
mellitus; antenatal bleeding; placental abruption; premature rupture of membranes; preterm delivery;
fetal distress; chorioamnionitis; or, maternal fever during or after labour. Lactation disorders was the only
secondary maternal outcome with a significantly increased hazard ratio. Tdap vaccine had a protective
effect on pre-eclampsia with severe features, preterm labour, preterm delivery, and antenatal bleeding.
Conclusion: We did not detect any biologically plausible adverse maternal outcomes following Tdap
vaccination during pregnancy. This study provides further assurance that Tdap administration during
pregnancy is not associated with unexpected safety risks.
2018 Published by Elsevier Ltd.

Publication 
Vaccine. 2018;36(34):5173-9.
Author 
Griffin JB, Yu L, Watson D, Turner N, Walls T, Howe AS, Jiang Y and Petousis-Harris H
Date 
2018
doi number 
10.1016/j.vaccine.2018.07.011
Type of Research 
Year 
2018
Menu Category 
Publication Date 
Thursday, July 5, 2018

Last updated: Sep 2018